Skip to main content
. Author manuscript; available in PMC: 2023 Dec 13.
Published in final edited form as: J Am Coll Cardiol. 2022 Nov 2;80(24):e223–e393. doi: 10.1016/j.jacc.2022.08.004

Recommendations for BP Management in TAA

Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR LOE RECOMMENDATIONS
1 B-NR 1. In patients with TAA and an average systolic BP (SBP) of ≥130 mm Hg or an average diastolic BP (DBP) of ≥80 mm Hg, the use of antihypertensive medications is recommended to reduce risk of cardiovascular events.13
2a C-LD 2. In patients with TAA, regardless of cause and in the absence of contraindications, use of beta blockers to achieve target BP goals is reasonable.1,4,5
2a C-EO 3. In patients with TAA, regardless of etiology and in the absence of contraindications, ARB therapy is a reasonable adjunct to betablocker therapy to achieve target BP goals.6